Search Results for:

Now Available! Updated Goodwin’s Guide to Biosimilars Litigation and Regulation in the U.S., 2020-2021

As regular Big Molecule Watch readers know, the Biologics Price Competition and Innovation Act (“BPCIA”) was signed into law as part of the Affordable Care Act on March 23, 2010, creating an abbreviated licensure pathway for “biosimilar” and “interchangeable” biological products. The BPCIA also introduced a new scheme to resolve…

Read More